Case series adds clinical evidence for ILE in pet neurotoxicosis: full analysis

A new veterinary case series is adding clinical data to one of toxicology’s more debated rescue therapies. In 34 dogs and cats with suspected neurotoxicosis treated with intravenous lipid emulsion, researchers found xenobiotics were generally more concentrated in the plasma lipid fraction than the aqueous fraction after treatment, and animals with higher lipid-to-aqueous ratios were more likely to show short-term neurologic improvement. The work, currently available as a 2026 preprint tied to eight European veterinary referral hospitals, stops short of proving causation, but it offers rare in vivo evidence that ILE may be altering xenobiotic distribution in actual clinical patients. (preprints.org)

That matters because ILE has been used in small animal toxicology for years, often on the basis of case reports, mechanistic theory, and clinician experience rather than strong prospective evidence. The therapy is intended to sequester lipophilic toxicants away from target tissues, but its real-world effect has been difficult to pin down. A large retrospective Frontiers in Veterinary Science study covering 313 dogs and 100 cats found apparent clinical improvement after ILE in 73.6% of patients overall, yet the authors also cautioned that improvement could not be confidently attributed to ILE alone because metabolism, elimination, and supportive care may also drive recovery. (frontiersin.org)

In the new case series, the final study population included 27 dogs and 7 cats that received a total ILE dose of 15 to 30 mL/kg completed within 70 minutes. Blood samples collected before and at the end of infusion were separated into lipid and aqueous fractions and analyzed by gas chromatography-mass spectrometry. Permethrin was the most frequently detected xenobiotic, followed by THC. Across the cohort, the median log P was 4.1, with a range from -1.0 to 7.0. But despite the longstanding focus on lipophilicity, the authors found no meaningful association between published log P values and lipid-to-aqueous partitioning or early neurologic outcome. (preprints.org)

Instead, the signal clinicians may care most about was the association between higher lipid-to-aqueous ratios and short-term neurologic improvement within a 4- to 6-hour observation window. The authors argue that this supports in vivo partitioning after ILE, while also suggesting that log P alone may be too blunt a proxy for bedside decision-making. They note several reasons why, including ionization at physiologic pH, protein binding, metabolites, co-therapies, and patient-level factors such as hemodynamics. They also acknowledge important limitations: modest post-exclusion numbers, very small toxin- and species-specific subgroups, and limited ability to assess dose-response or clustering effects. (preprints.org)

Industry and expert context remains cautious. The MSD Veterinary Manual states that not all clinically affected animals respond positively to intralipid therapy, and specifically notes worsening has been reported with some intoxications, including bromethalin and calcium channel blockers. In the large 2023 Frontiers series, presumed adverse effects occurred in 5.8% of patients after ILE. Human toxicology literature points in the same direction: a 2025 narrative review described the evidence base as limited and noted that some expert groups advise against routine use in certain severe poisonings, citing uncertain efficacy and potential complications. (msdvetmanual.com)

Why it matters: For veterinary professionals, this study doesn’t settle the ILE debate, but it does sharpen it. The paper gives clinicians something more concrete than anecdote by showing measurable post-infusion partitioning in real canine and feline cases. At the same time, it argues against relying too heavily on textbook lipophilicity values when deciding whether ILE is likely to help. In practice, that could push ER and ICU teams toward a more nuanced framework that weighs the suspected toxicant, neurologic severity, timing of exposure, concurrent therapies, and the possibility of adverse effects, rather than treating log P as a shortcut. (preprints.org)

The findings may be especially relevant in common neurotoxicosis presentations such as permethrin exposure in cats or cannabis intoxication in dogs, both of which appeared prominently in the cohort. But the study’s design also reflects everyday reality: mixed toxicants, imperfect histories, and supportive care happening alongside antidotal therapy. That makes the results clinically relatable, even if they’re not definitive. For hospitals that already use ILE selectively, this paper may support continued use in carefully chosen cases. For those that are more hesitant, it provides a reminder that the mechanistic story is stronger than the outcomes evidence. (preprints.org)

What to watch: The next step is peer-reviewed publication and, ideally, larger prospective studies that compare ILE-treated patients with matched controls, track longer neurologic and survival outcomes, and better define which toxicants and clinical scenarios justify treatment. Until then, ILE looks more like a targeted rescue therapy than a broadly reliable antidote. (research-portal.uu.nl)